المؤلفون: S. Yu. Dobner, S. V. Fedosenko, A. Yu. Dobrodeev, N. D. Yarovoy, E. N. Samtsov, А. V. Dubakov, E. A. Starovoitova, О. A. Denisova, N. A. Kirillova, С. Ю. Добнер, С. В. Федосенко, А. Ю. Добродеев, Н. Д. Яровой, Е. Н. Самцов, А. В. Дубаков, Е. А. Старовойтова, О. А. Денисова, Н. А. Кириллова

المصدر: Siberian journal of oncology; Том 22, № 5 (2023); 49-59 ; Сибирский онкологический журнал; Том 22, № 5 (2023); 49-59 ; 2312-3168 ; 1814-4861

مصطلحات موضوعية: тиотропия бромид, perioperative period, chronic obstructive pulmonary disease, bronchodilator therapy, tiotropium bromide, периоперационный период, хроническая обструктивная болезнь легких, бронхолитическая терапия

وصف الملف: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/2760/1158; Young R.P., Hopkins R.J., Christmas T., Black P.N., Metcalf P., Gamble G.D. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J. 2009; 34(2): 380–6. doi:10.1183/09031936.00144208.; Kondo R., Yoshida K., Eguchi T., Kobayashi N., Saito G., Hamanaka K., Shiina T., Kurai M. Clinical features of lung cancer in smokers with light and mild chronic obstructive pulmonary disease: a retrospective analysis of Japanese surgical cases. Eur J Cardiothorac Surg. 2011; 40(6): 1439–43. doi:10.1016/j.ejcts.2011.03.017.; Vermaelen K., Brusselle G. Exposing a deadly alliance: novel insights into the biological links between COPD and lung cancer. Pulm Pharmacol Ther. 2013; 26(5): 544–54. doi:10.1016/j.pupt.2013.05.003.; Murakami J., Ueda K., Sano F., Hayashi M., Nishimoto A., Hamano K. Pulmonary emphysema and tumor microenvironment in primary lung cancer. J Surg Res. 2016; 200(2): 690–7. doi:10.1016/j.jss.2015.09.004.; Добнер С.Ю., Федосенко С.В., Родионов Е.О., Яровой Н.Д., Петров В.А., Тузиков С.А., Старовойтова Е.А., Самыкина И.А. Рак легкого у больных ХОБЛ и факторы, ассоциированные со снижением их выживаемости. Бюллетень сибирской медицины. 2022; 21(3): 41–9. doi:10.20538/16820363-2022-3-41-49.; Brunelli A., Kim A.W., Berger K.I., Addrizzo-Harris D.J. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 s): 166–90. doi:10.1378/chest.12-2395. Erratum in: Chest. 2014; 145(2): 437.; Белялова Н.С., Дворниченко В.В., Менг А.А., Моклоков А.В., Лелявин Б.И., Сокольников М.В., Улыбин П.С., Хаматов Р.К. Факторы риска хирургии легких: возраст и респираторная функция. Российский онкологический журнал. 2009; (1): 48–9.; Adcock I.M., Caramori G., Barnes P.J. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration. 2011; 81(4): 265–84. doi:10.1159/000324601.; Roy E., Rheault J., Pigeon M.A., Ugalde P.A., Racine C., Simard S., Chouinard G., Lippens A., Lacasse Y., Maltais F. Lung cancer resection and postoperative outcomes in COPD: A single-center experience. Chron Respir Dis. 2020; 17. doi:10.1177/1479973120925430.; Venkatesan P. GOLD COPD report: 2023 update. Lancet Resp Med. 2022; 11(1). doi:10.1016/S2213-2600(22)00494-5.; González J., Henschke C.I., Yankelevitz D.F., Seijo L.M., Reeves A.P., Yip R., Xie Y., Chung M., Sánchez-Salcedo P., Alcaide A.B., Campo A., Bertó J., Del Mar Ocón M., Pueyo J., Bastarrika G., de-Torres J.P., Zulueta J.J. Emphysema phenotypes and lung cancer risk. PLoS One. 2019 Jul 25; 14(7). doi:10.1371/journal.pone.0219187.; Akira M., Toyokawa K., Inoue Y., Arai T. Quantitative CT in chronic obstructive pulmonary disease: inspiratory and expiratory assessment. Am J Roentgenol. 2009; 192(1): 267–72. doi:10.2214/AJR.07.3953.; https://www.siboncoj.ru/jour/article/view/2760

الاتاحة: https://www.siboncoj.ru/jour/article/view/2760
https://doi.org/10.21294/1814-4861-2023-22-5-49-59

المؤلفون: O. N. Titova, N. A. Kuzubova, A. G. Kozyrev, О. Н. Титова, Н. А. Кузубова, А. Г. Козырев

المساهمون: The article was prepared with the support of PSK Pharma LLC (Russia) in accordance with the current legislation of the Russian Federation and the principles of Good Clinical Practice in scientific publications, Статья подготовлена при поддержке компании ООО «ПСК Фарма» (Россия) в соответствии с действующим законодательством Российской Федерации и принципами Добросовестной практики научных публикаций

المصدر: PULMONOLOGIYA; Том 33, № 6 (2023); 810-818 ; Пульмонология; Том 33, № 6 (2023); 810-818 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: Респиум®, long-acting muscarinic antagonist, tiotropium bromide, Respium®, длительно действующий антихолинергический препарат, тиотропия бромид

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/4394/3585; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2316; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2318; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2319; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2320; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2321; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4394/2322; Всемирная организация здравоохранения. Информационные бюллетени. Хроническая обструктивная болезнь легких (ХОБЛ). Доступно на: https://www.who.int/ru/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd); Adeloye D., Song P., Zhu Y. et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir. Med. 2022; 10 (5): 447–458. DOI:10.1016/S2213-2600(21)00511-7.; GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021; 397 (10292): 2337–2360. DOI:10.1016/S0140-6736(21)01169-7.; Lange P., Marott J.L., Vestbo J. et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am. J. Respir. Crit. Care Med. 2012; 186 (10): 975–981. DOI:10.1164/rccm.201207-1299OC.; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 Report. Available at: https://goldcopd.org/2023-gold-report-2/; Авдеев С.Н., Лещенко И.В., Айсанов З.Р. Новая концепция и алгоритм ведения пациентов с хронической обструктивной болезнью легких. Пульмонология. 2023; 33 (5): 587–594. DOI:10.18093/0869-0189-2023-33-5-587-594.; Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103. DOI:10.1056/NEJMoa1008378.; Decramer M.L., Chapman K.R., Dahl R. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 2013; 1 (7): 524–533. DOI:10.1016/S2213-2600(13)70158-9.; Panning C.A., DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy. 2003; 23 (2): 183–189. DOI:10.1592/phco.23.2.183.32082.; van Noord J.A., Bantje T.A., Eland M.E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000; 55 (4): 289–294. DOI:10.1136/thorax.55.4.289.; Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161 (4, Pt 1): 1136–1142. DOI:10.1164/ajrccm.161.4.9903044.; Niewoehner D.E., Lapidus R., Cote C. et al. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2009; 22 (6): 587–592. DOI:10.1016/j.pupt.2009.08.006.; Cooper C.B. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am. J. Med. 2006; 119 (10, Suppl. 1): 21–31. DOI:10.1016/j.amjmed.2006.08.004.; O'Donnell D.E., Flüge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23 (6): 832–840. DOI:10.1183/09031936.04.00116004.; Verkindre C., Bart F., Aguilaniu B. et al. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration. 2006; 73 (4): 420–427. DOI:10.1159/000089655.; Fležar M., Jahnz-Różyk K., Enache G. et al. SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 483–492. DOI:10.2147/COPD.S45640.; Jahnz-Różyk K., Szepiel P. Early impact of treatment with tiotropium, long-acting anticholinergic preparation, in patients with COPD – real-life experience from an observational study. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 613–623. DOI:10.2147/COPD.S77144.; Wallace A.E., Kaila S., Bayer V. et al. Health care resource utilization and exacerbation rates in patients with COPD stratified by disease severity in a commercially insured population. J. Manag. Care Spec. Pharm. 2019; 25 (2): 205–217. DOI:10.18553/jmcp.2019.25.2.205.; Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143 (5): 317–326. DOI:10.7326/0003-4819-143-5-200509060-00007.; Barr R.G., Bourbeau J., Camargo C.A., Ram F.S.F. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2006; 61 (10): 854–862. DOI:10.1136/thx.2006.063271.; Dusser D., Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27 (3): 547–555. DOI:10.1183/09031936.06.00062705.; Halpin D.M., Vogelmeier C., Pieper M.P. et al. Effect of tiotropium on COPD exacerbations: a systematic review. Respir. Med. 2016; 114: 1–8. DOI:10.1016/j.rmed.2016.02.012.; Calzetta L., Coppola A., Ritondo B.L. et al. The impact of muscarinic receptor antagonists on airway inflammation: a systematic review. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 257–279. DOI:10.2147/COPD.S285867.; Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26. DOI:10.1164/rccm.200707-973OC.; Cheyne L., Irvin-Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015; 2015 (9): CD009552. DOI:10.1002/14651858.CD009552.pub3.; Griffin J., Lee S., Caiado M. et al. Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: a UK General Practice Research Database 12-month follow-up study. Prim. Care Respir. J. 2008; 17 (2): 104–110. DOI:10.3132/pcrj.2008.00024.; Chapman K.R., Beeh K.M., Beier J. et al. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm. Med. 2014; 14: 4. DOI:10.1186/1471-2466-14-4.; Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI:10.1016/S2213-2600(13)70052-3.; Beier J., Kirsten A.M., Mróz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD. 2013; 10 (4): 511–522. DOI:10.3109/15412555.2013.814626.; Титова О.Н., Кузубова Н.А., Козырев А.Г., Шумилов А.А. Бронхолитическая терапия при хронической обструктивной болезни легких: что следует учитывать в клинической практике при выборе режима дозирования? Пульмонология. 2023; 33 (1): 44–50. DOI:10.18093/0869-0189-2023-33-1-44-50.; Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554. DOI:10.1056/NEJMoa0805800.; Rodrigo G.J., Castro-Rodriguez J.A., Nannini L.J. et al. Tiotropium and risk for fatal and nonfatal cardiovascular events in patients with chronic obstructive pulmonary disease: systematic review with meta-analysis. Respir. Med. 2009; 103 (10): 1421–1429. DOI:10.1016/j.rmed.2009.05.020.; Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–1501. DOI:10.1056/NEJMoa1303342.; Halpin D.M., Dahl R., Hallmann C. et al. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 239–259. DOI:10.2147/COPD.S75146.; Anzueto A., Wise R., Calverley P. et al. The Tiotropium safety and performance in Respimat® (TIOSPIR®) trial: spirometry outcomes. Respir. Res. 2015; 16 (1): 107. DOI:10.1186/s12931-015-0269-4.; Capstick T.G., Clifton I.J. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev. Respir. Med. 2012; 6 (1): 91–101. DOI:10.1586/ers.11.89.; Государственный реестр лекарственных средств. Сведения о лекарственном средстве Респиум®. Доступно на: https://grls.rosminzdrav.ru/grls.aspx?s=%D0%9B%D0%9F-006263&m=RegistrationCertificateNumber; The COPD Assessment Test (CAT). Available at: https://www.catestonline.org/; Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC. Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). Br. Med. J. 1960; 2 (5213): 1665. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2098438/?page=1; https://journal.pulmonology.ru/pulm/article/view/4394

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/4394
https://doi.org/10.18093/0869-0189-2023-33-6-810-818

المؤلفون: S. Yu. Dobner, S. A. Tuzikov, T. S. Аgeeva, E. N. Samtsov, A. V. Dubakov, I. G. Sinilkin, A. Yu. Dobrodeev

المصدر: Сибирский онкологический журнал, Vol 19, Iss 1, Pp 111-118 (2020)

مصطلحات موضوعية: рак легкого, хроническая обструктивная болезнь легких, легочная реабилитация, длительно действующие бронхолитики, тиотропия бромид в ингаляторе – респимат, функция внешнего дыхания, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.siboncoj.ru/jour/article/view/1330; https://doaj.org/toc/1814-4861; https://doaj.org/toc/2312-3168

URL الوصول: https://doaj.org/article/7d9e77835d63472982cdb4b89a46e7a7

المؤلفون: S. К. Zyryanov, I. N. Dyakov, С. К. Зырянов, И. Н. Дьяков

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 15, No 2 (2022); 188-198 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 15, No 2 (2022); 188-198 ; 2070-4933 ; 2070-4909

مصطلحات موضوعية: реальная клиническая практика, COPD, GOLD D, tiotropium bromide + olodaterol, monotherapy, combination therapy, budget impact, exacerbations, long-acting bronchodilator, long-acting M-cholinolytic, real clinical practice, ХОБЛ, тиотропия бромид + олодатерол, монотерапия, комбинированная терапия, влияние на бюджет, обострения, бронходилататор длительного действия, М-холинолитик длительного действия

وصف الملف: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/688/423; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. URL: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf (дата обращения 03.06.2022).; Хроническая обструктивная болезнь легких. Клинические рекомендации. Минздрав РФ. 2021. URL: https://cr.minzdrav.gov.ru/recomend/603_2 (дата обращения 03.06.2022).; Lamprecht B., McBurnie M.A., Vollmer W.M., et al. COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest. 2011; 139 (4): 752–63. https://doi.org/10.1378/chest.10-1253.; Chuchalin A.G., Khaltaev N., Antonov N.S., et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014; 9: 963–74. https://doi.org/10.2147/COPD.S67283.; Nguyen T. Evidence-informed policy making: bridging the gap. Public Health Panorama. 2016; 2: 257.; van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 2012; 21 (1): 101–8. https://doi.org/10.4104/pcrj.2011.00102.; Mahler D.A., Decramer M., D’Urzo A., et al. Dual bronchodilatation with QVA149 reduces patient reported dyspnea in COPD: the BLAZE study. Eur Respir J. 2014; 43 (6): 1599–609. https://doi.org/10.1183/09031936.00124013.; Arkhipov V., Arkhipova D., Miravitlles M., et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int J Chron Obstruct Pulmon Dis. 2017; 12: 3255–62. https://doi.org/10.2147/COPD.S142997.; Calverley P.M., Anzueto A.R., Carter K., et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir Med. 2018; 6 (5): 337–44. https://doi.org/10.1016/S2213-2600(18)30102-4.; Decramer M.L., Chapman K.R., Dahl R., et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013; 1 (7): 524–33. https://doi.org/10.1016/S2213-2600(13)70158-9.; Sethi S., Kerwin E., Watz H., et al. AMPLIFY: a randomized, phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14: 667–82. https://doi.org/10.2147/COPD.S189138.; Государственный реестр предельных отпускных цен. URL: https://grls.rosminzdrav.ru/pricelims.aspx (дата обращения 03.06.2022).; Постановление Правительства РФ от 28.12.2021 № 2505. «О Программе государственных гарантий бесплатного оказания гражданам медицинской помощи на 2022 год и на плановый период 2023 и 2024 годов». URL: https://base.garant.ru/403335795/ (дата обращения 03.06.2022).; Приказ Минздрава России от 20.12.2012 № 1214н «Об утверждении стандарта первичной медико-санитарной помощи при обострении хронической обструктивной болезни легких». URL: https://minzdrav.gov-murman.ru/documents/poryadki-okazaniya-meditsinskoy-pomoshchi/pr_MZ_RF_1214.pdf (дата обращения 03.06.2022).; Федеральная служба государственной статистики. URL: https://rosstat.gov.ru (дата обращения 03.06.2022).; Karner C., Cates C.J. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011; 3: CD008532. https://doi.org/10.1002/14651858.CD008532.pub2.; https://www.pharmacoeconomics.ru/jour/article/view/688

الاتاحة: https://www.pharmacoeconomics.ru/jour/article/view/688
https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.144

المؤلفون: A. G. Romanovskikh, A. I. Sinopal’nikov, Yu. G. Belotserkovskaya, I. P. Smirnov, А. Г. Романовских, А. И. Синопальников, Ю. Г. Белоцерковская, И. П. Смирнов

المساهمون: This publication is supported by Boehringer Ingelheim LLC, Статья опубликована при финансовой поддержке ООО Берингер Ингельхейм

المصدر: PULMONOLOGIYA; Том 31, № 4 (2021); 511-516 ; Пульмонология; Том 31, № 4 (2021); 511-516 ; 2541-9617 ; 0869-0189

مصطلحات موضوعية: комбинации тиотропия бромид / олодатерол. Конфликт интересов, cardiovascular diseases, pharmacotherapy of COPD, tiotropium/olodaterol, сердечно-сосудистые заболевания, фармакотерапия хронической обструктивной болезни легких

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/2414/1865; Российское респираторное общество. Хроническая обструктивная болезнь легких: Федеральные клинические рекомендации. 2018. Доступно на: https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf [Дата обращения: 05.01.21].; Vanfleteren L.E.G., Spruit M.A., Groenen M. et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013; 187 (7): 728–735. DOI:10.1164/rccm.201209-1665OC.; Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33 (5): 1165–1185. DOI:10.1183/09031936.00128008.; Antonelli Incalzi R., Fuso L., De Rosa M. et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10 (12): 2794–2800. DOI:10.1183/09031936.97.10122794.; Morgan A.D., Zakeri R., Quint J.K. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther. Adv. Respir. Dis. 2018; 12: 1753465817750524. DOI:10.1177/1753465817750524.; Curkendall S.M., Lanes S., de Luise C. et al. Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur. J. Epidemiol. 2006; 21 (11): 803–813. DOI:10.1007/s10654-006-9066-1.; Mannino D.M., Thorn D., Swensen A., Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 2008; 32 (4): 962–969. DOI:10.1183/09031936.00012408.; Almagro P., López F., Cabrera F.J. et al. [Comorbidities in patients hospitalized due to chronic obstructive pulmonary disease. A comparative analysis of the ECCO and ESMI studies]. Rev. Clin. Esp. 2012; 212 (6): 281–286. DOI:10.1016/j.rce.2012.02.014 (in Spanish).; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 Report. Available at: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORTver1.0wms.pdf [Available at: June 28, 2021].; Hohlfeld J.M., Vogel-Claussen J., Biller H. et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir. Med. 2018; 6 (5): 368–378. DOI:10.1016/S2213-2600(18)30054-7.; Rogliani P., Matera M.G., Ritondo B.L. et al. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations. Pulm. Pharmacol. Ther. 2019; 59: 101841. DOI:10.1016/j.pupt.2019.101841.; Calverley P.M.A., Anzueto A.R., Carter K. et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir. Med. 2018; 6 (5): 337–344. DOI:10.1016/S2213-2600(18)30102-4.; Andreas S., McGarvey L., Bothner U. et al. Absence of adverse effects of tiotropium/olodaterol compared with the monocomponents on long-term heart rate and blood pressure in patients with moderate-to-very-severe COPD. Int. J. Chron. Obstruct. Pulmon Dis. 2020; 15: 1935–1944. DOI:10.2147/COPD.S246348.; Ferguson G.T., Buhl R., Bothner U. et al. Safety of tiotropium/ olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respir. Med. 2018; 143: 67–73. DOI:10.1016/j.rmed.2018.08.012.; Valipour A., Avdeev S., Barczyk A. et al. Therapeutic success of tiotropium/olodaterol, measured using the Clinical COPD Questionnaire (CCQ), in routine clinical practice: A multinational non-interventional study. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 615–628. DOI:10.2147/COPD.S291920.; https://journal.pulmonology.ru/pulm/article/view/2414

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/2414
https://doi.org/10.18093/0869-0189-2021-31-4-511-516

المؤلفون: I. Demko V., N. Gordeeva V., A. Kraposhina Yu., M. Mamaeva G., I. Soloveva A., И. Демко В., Н. Гордеева В., А. Крапошина Ю., М. Мамаева Г., И. Соловьева А.

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2020); 90-95 ; Медицинский Совет; № 21 (2020); 90-95 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: chronic obstructive pulmonary disease, bronchodilators, long acting beta agonists, long acting muscarinic antagonists, Vilanterol, Umeclidinium, olodaterol, Tiotropium bromide, хроническая обструктивная болезнь легких, бронходилататоры, длительнодействующий антихолинергический препарат, длительнодействующий β2-агонист, вилантерол, умеклидиний, олодатерол, тиотропия бромид

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5970/5450; Кулик Е.Г., Павленко В.И., Нарышкина С.В. Вероятностная оценка обострений у больных ХОБЛ категории низкого риска на фоне долгосрочного лечения рофлумиластом. Амурский медицинский журнал. 2019;(3):19–22. Режим доступа: https://elibrary.ru/item.asp?id=41440324.; Зырянов С.К., Галатонова Ю.А. Клиническая и фармакоэкономическая оценка применения комбинации тиотропия бромида и олодатерола у пациентов с хронической обструктивной болезнью легких. Медицинский совет. 2018;(6):61–65. doi:10.21518/2079-701X-2018-6-61-65.; Chuchalin A.G., Khaltaev N., Antonov N.S., Galkin B.V., Manakov L.G., Antonini P. et al. Chronic respiratory pulmonary diseases and risk factors in 12 regions of the Russian Federation. Int J COPD. 2014;9(1):963–974. doi:10.2147/COPD.S67283.; Демко И.В., Мамаева М.Г., Гордеева Н.В., Соловьева И.А., Крапошина А.Ю. Клинический опыт применения двойной бронходилатационной терапии у пациентов с ХОБЛ. Медицинский совет. 2019;(15):7–10. doi:10.21518/2079-701X-2019-15-7-10.; Романовских А.Г., Белоцерковская Ю.Г., Стырт Е.А. Современные подходы к фармакотерапии хронической обструктивной болезни легких: место фиксированных комбинированных препаратов. Клиническая медицина. 2015;93(12):38–43. Режим доступа: https://elibrary.ru/item.asp?id=25401657.; Авдеев С.Н., Айсанов З.Р., Белевский А.С., Визель А.А., Зырянов С.К., Игнатова Г.Л. и др. Новые возможности в профилактике обострений хронической обструктивной болезни легких. Заключение группы специалистов Российского респираторного общества. Пульмонология. 2017;27(1):108–113. doi:10.18093/0869-0189-2017-27-1-108-113.; Синопальников А.И. Фиксированные комбинации бронходилататоров в лечении больных ХОБЛ: проблема выбора. Медицинский совет. 2018;(15):96–100. doi:10.21518/2079-701X-2018-15-96-1006.; Riley C.M., Sciurba F.C. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA. 2019;321(8):786–797. doi:10.1001/jama.2019.0131.; Лещенко И.В. Фиксированные комбинации длительно действующих бронходилататоров при хронической обструктивной болезни легких: безопасность, эффективность и сердечно-сосудистая система. Медицинский совет. 2018;(15):18–26. doi:10.21518/2079-701X-2018-15-18-26.; Calzetta L., Matera, M.G., Cazzola M. Pharmacological interaction between LABAs and LAMAs in the respiratory tract: optimization of synergy. Eur J Pharmacol. 2015;(761):168–173. doi:10.1016/j.ejphar.2015.05.020.; Ferguson G.T., Flezar M., Korn S., Korducki L., Grönke L., Abrahams R., Buhl R. Efficacy of tio tropium+olodaterol in patients with chronic obstructive pul monary disease by initial disease severity and treatment inten sity: a post hoc analysis. Adv Ther. 2015;32(6):523–536. doi:10.1007/s12325-015-0218-0.; Beeh K.M., Westerman J., Kirsten A.M., Hébert J., Grönke L., Hamilton A. et al. The 24h lung function profile of once daily tiotropium and olodaterol fixed dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;(32):53–59. doi:10.1016/j.pupt.2015.04.002.; Игнатова Г.Л., Антонов В.Н. Небулайзерная терапия при заболеваниях легких. Медицинский совет. 2020;(11):102–106. doi:10.21518/2079-701X-2020-11-102-106.; Cazzola M., Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. doi:10.1016/j.pupt.2010.03.003.; Визель А.А., Визель И.Ю., Бакунина Е.А. Хроническая обструктивная болезнь легких: современные подходы к терапии. Медицинский совет. 2016;(15):6–10. doi:10.21518/2079-701X-2016-15-6-10.; Calzetta L., Rogliani P., Matera M.G., Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Сhest. 2016;149(5):1181–1196. doi:10.1016/j.chest.2016.02.646.; Donohue J.F., Maleki-Yazdi M.R., Kilbride S, Mehta R., Kalberg C., Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.001.; Авдеев С.Н., Айсанов З.Р., Белевский А.С. Клинические рекомендации Российского респираторного общества: Алгоритм ведения больных ХОБЛ. Терапия. 2017;(4):102–106. Режим доступа: https://therapy-journal.ru/ru/archive/article/35046.; Свидерская Л.Н., Симакова В.М., Демко И.В., Хендогина В.Т., Кудрявцева А.Н., Третьяк Т.В. и др. Сравнительная оценка организации контроля доступности и качества оказания медицинской помощи в условиях краевой консультативной поликлиники. Сибирское медицинское обозрение. 2016;(5):53–64. Режим доступа: https://elibrary.ru/item.?id=27487911.; Singh D., Ferguson G.T., Bolitschek J., Grönke L., Hallmann C., Bennett N. et al. Tiotropium + olodaterol shows clinically meaningful improvements in qual ity of life. Respir Med. 2015;109(10):1312–1319. doi:10.1016/j.rmed.2015.08.002.; Трушенко Н.В., Сопова М.И., Сопова В.И. Фенотипы хронической обструктивной болезни легких – путь к персонифицированной терапии. Практическая пульмонология. 2019;(3):32–39. Режим доступа: https://elibrary.ru/item.asp?id=42211538.; Blair H.A., Deeks E.D. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs. 2015;75(1):61–74. doi:10.1007/s40265-014-0326-1.; Feldman G.J., Sousa A.R., Lipson D.A., Tombs L., Barnes N., Riley J.H. et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv Ther. 2017;34(1):2518–2533. doi:10.1007/s12325-017-0626-4.; Calzetta L., Matera M.G., Cazzola M., Rogliani P. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. Adv Ther. 2019;36(12):3291–3298. doi:10.1007/s12325- 019-01119-w.; Толкушин А.Г., Погудина Н.Л. Фармакоэкономический анализ лекарственного лечения хронической обструктивной болезни легких: вилантерол + умеклидиния бромид по сравнению с другими комбинациями длительно действующих ß-агонистов и антихолинергетиков. Медицинские технологии. Оценка и выбор. 2018;(3):75–88. doi:10.31556/2219-0678.2018.33.3.075-088.; Зыков К.А., Овчаренко С.И. Подходы к лекарственной терапии больных ХОБЛ стабильного течения: предлагаемый алгоритм лечения. Медицинский совет. 2015;(17):24–31. doi:10.21518/2079-701X-2015-17-24-31.; Авдеев С.Н., Айсанов З.Р. Максимальная бронходилатация со старта терапии хронической обструктивной болезни легких: влияние на течение заболевания. Пульмонология. 2016;26(5):604–609. doi:10.18093/0869-0189-2016-26-5-604-609.; https://www.med-sovet.pro/jour/article/view/5970

الاتاحة: https://www.med-sovet.pro/jour/article/view/5970
https://doi.org/10.21518/2079-701X-2020-21-90-95

المؤلفون: Zyryanov S.K., Galatonova Y.A.

المصدر: Медицинский совет

مصطلحات موضوعية: тиотропия бромид, олодатерол, фармакоэкономический анализ, tiotropium-olodaterol, Copd, Respimat, хобл, респимат

Relation: https://doi.org/10.21518/2079-701X-2018-6-61-65; https://openrepository.ru/article?id=245729

الاتاحة: https://openrepository.ru/article?id=245729

المؤلفون: Kulynych-Miskiv, M. (Mariana), Ostrovskyy, M. (Mykola), Savelikhina, I. (Iryna), Ostrovska, K. (Kseniya), Varunkiv, O. (Oleksander)

المصدر: ScienceRise: Medical Science

مصطلحات موضوعية: хронічні обструктивні захворювання легень, тіотропію бромід, функція зовнішнього дихання, УДК 616.223.002+616-071-059+547.914+576.8.007.3+616.24-073.173, хронические обструктивные заболевания легких, тиотропия бромид, функция внешнего дыхания, chronic obstructive pulmonary diseases, tiotropium bromide, external respiratory function, Indonesia

وصف الملف: application/pdf

Relation: https://www.neliti.com/publications/313626/%D0%BE%D1%81%D0%BE%D0%B1%D0%BB%D0%B8%D0%B2%D0%BE%D1%81%D1%82%D1%96-%D0%BF%D0%BE%D1%80%D1%83%D1%88%D0%B5%D0%BD%D1%8C-%D1%84%D1%83%D0%BD%D0%BA%D1%86%D1%96%D1%97-%D0%B7%D0%BE%D0%B2%D0%BD%D1%96%D1%88%D0%BD%D1%8C%D0%BE%D0%B3%D0%BE-%D0%B4%D0%B8%D1%85%D0%B0%D0%BD%D0%BD%D1%8F-%D1%83-%D0%BF%D0%B0%D1%86%D1%96%D1%94%D0%BD%D1%82%D1%96%D0%B2-%D0%B7-%D1%85%D1%80%D0%BE%D0%BD%D1%96%D1%87%D0%BD%D0%B8%D0%BC-%D0%BE%D0%B1%D1%81%D1%82%D1%80%D1%83%D0%BA

الاتاحة: https://www.neliti.com/publications/313626/%D0%BE%D1%81%D0%BE%D0%B1%D0%BB%D0%B8%D0%B2%D0%BE%D1%81%D1%82%D1%96-%D0%BF%D0%BE%D1%80%D1%83%D1%88%D0%B5%D0%BD%D1%8C-%D1%84%D1%83%D0%BD%D0%BA%D1%86%D1%96%D1%97-%D0%B7%D0%BE%D0%B2%D0%BD%D1%96%D1%88%D0%BD%D1%8C%D0%BE%D0%B3%D0%BE-%D0%B4%D0%B8%D1%85%D0%B0%D0%BD%D0%BD%D1%8F-%D1%83-%D0%BF%D0%B0%D1%86%D1%96%D1%94%D0%BD%D1%82%D1%96%D0%B2-%D0%B7-%D1%85%D1%80%D0%BE%D0%BD%D1%96%D1%87%D0%BD%D0%B8%D0%BC-%D0%BE%D0%B1%D1%81%D1%82%D1%80%D1%83%D0%BA

المؤلفون: Р. Balunov A., A. Khitrov N., П. Балунов А., А. Хитров Н.

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2018); 96-104 ; Медицинский Совет; № 21 (2018); 96-104 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-21

مصطلحات موضوعية: chronic obstructive pulmonary disease, pharmacoeconomic analysis, tiotropium bromide, fenoterol, ipratropium bromide, Ipraterol-nativ, Tiotropium-nativ, хроническая обструктивная болезнь легких, фармакоэкономический анализ, тиотропия бромид, фенотерол, ипратропия бромид, Ипратерол-натив, Тиотропиум-натив

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2822/2766; Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2019 Report. https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.6-FINAL-08Nov2018-wms.pdf.; Хроническая обструктивная болезнь легких. Клинические рекомендации. 2018. http://spulmo.ru/obrazovatelnye-resursy/federalnyeklinicheskie-rekomendatsii/.; Gino Scalone. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL – The prospective cohort, observational study. Pulmonary Pharmacology & Therapeutics. 2018; 53: 68-77/; Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006; 27(2): 397-412.; World Health Organization. Projections of mortality and causes of death, 2015 and 2030. http://www.who.int/healthinfo/global_burden_disease/projections/en/ (accessed 14 October 2018).; Adeloye D., Chua S., Lee C., Basquill C., Papana A., Theodoratou E., Nair H., Gasevic D., Sridhar D., Campbell H. et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015; 5.; Хроническая обструктивная болезнь легких: руководство для практикующих врачей. С.И. Овчаренко, И.В. Лещенко [и др.]. Под ред. А.Г. Чучалина. М.: ГЭОТАР-Медиа, 2016. 192 с. (Серия «Библиотека врача-специалиста»). ISBN 978-5-9704-3578-6.; Курение и хроническая обструктивная болезнь легких. Киров: ЭВ, ЦМП КОГБУЗ «МИАЦ», 2017. http://sovetskcrb.medkirov.ru/.; COPD http://hobl-online.ru/.; Miller J.D., Foster T., Boulanger L. et al. Direct costs of COPD in the U.S.: an analysis of Medical Expenditure Panel Survey (MEPS) data. COPD. 2005; 2: 311-318.; Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2014 г.). Пер. с англ. под ред. А.С. Белевского. М.: Российское респираторное общество, 2014. 92 с., ил.; Celli B.R., MacNee W., Agusti A. et al. European Respiratory Journal. 2004; 23 (6): 932-946.; Недогода С.В., Цома В.В., Ледяева А.А., Хрипаева В.Ю. Современные возможности терапии ХОБЛ в России: от клинических рекомендаций к реальной практике. Эффективная фармакотерапия. 2017; 14: 24-32.; Визель А.А., Ермолова С.О., Бердникова Н.Г. и др. Бронхолитическая терапия в реальной клинической практике: сравнение оригинального иностранного и отечественного воспроизведенного препаратов. РМЖ. Пульмонология. 2017; 25, 18: 1275–1280.; Государственный реестр предельных отпускных цен. http://grls.rosminzdrav.ru/PriceLims.aspx.; Макарова М.А. Курение и хроническая обструктивная болезнь легких. Астма и аллергия. 2016; 4: 19-20.; https://www.med-sovet.pro/jour/article/view/2822

الاتاحة: https://www.med-sovet.pro/jour/article/view/2822
https://doi.org/10.21518/2079-701X-2018-21-96-104

المؤلفون: S. K. Zyryanov, I. N. D'yakov, С. К. Зырянов, И. Н. Дьяков

المصدر: PULMONOLOGIYA; Том 28, № 1 (2018); 61-68 ; Пульмонология; Том 28, № 1 (2018); 61-68 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2018-28-1

مصطلحات موضوعية: анализ влияния на бюджет, long-acting bronchodilators, indacaterol, tiotropium bromide, glycopyrronium bromide/indacaterol, economic burden, budget impact analysis on the, бронходилататоры длительного действия, длительно действующие β2-агонисты, длительно действующие М-холинолитические препараты, индакатерол, тиотропия бромид, гликопиррония бромид + индакатерол, клинико-экономическая оценка

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/962/805; Синопальников А.И., Зайцев А.А. Антибактериальная терапия обострений хронического бронхита / хронической обструктивной болезни легких. Ключевые положения. Медицинский совет. 2017; 18: 14–20. DOI:10.21518/2079-701X-2017-18-14-20.; Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65 (6): 473–479. DOI:10.1136/thx.2009.125435.; Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI:10.1056/NEJMoa1516385.; Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209. DOI:10.1016/S2213-2600(13)70052-3.; Frampton J.E. QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease. Drugs. 2014; 74 (4): 465–488. DOI:10.1007/s40265-014-0194-8.; Banerji D., Fogel R., Patalano F. Indacaterol/glycopyrronium: a dual bronchodilator for COPD. Drug Discov. Today. 2018; 23 (1): 196–203. DOI:10.1016/j.drudis.2017.10.015.; Зырянов С.К., Фролов М.Ю., Белевский А.С. Клинико-экономическая эффективность применения фиксированной комбинации индакатерол / гликопиррония бромид при лечении хронической обструктивной болезни легких. Практическая пульмонология. 2016; (4): 76–84.; Donohue J. F., Betts K.A., Du E.X. et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Intern. J. COPD. 2017: 12: 367–381. DOI:10.2147/COPD.S119908.; Keininger D.L., Price D., Viswanad B. et al. Real-life experience of COPD patients on ease and accuracy of inhaler use: the REAL survey. J. Thorac. Dis. 2016; 8 (Suppl. 5): AB036. DOI:10.21037/jtd.2016.s036.; Molimard M., Raherison C., Lignot S. et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur. Respir. J. 2017; 49 (2): 1601794. DOI:10.1183/13993003.01794-2016.; https://journal.pulmonology.ru/pulm/article/view/962

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/962
https://doi.org/10.18093/0869-0189-2018-28-1-61-68

المؤلفون: A. F. Ivanov, B. A. Chernyak, А. Ф. Иванов, Б. А. Черняк

المصدر: Acta Biomedica Scientifica; Том 3, № 2 (2018); 25-29 ; 2587-9596 ; 2541-9420

مصطلحات موضوعية: тиотропия бромид, tiotropium bromide

وصف الملف: application/pdf

Relation: https://www.actabiomedica.ru/jour/article/view/554/555; Хельсинская декларация Всемирной медицинской ассоциации. Этические принципы проведения медицинских исследований с участием человека в качестве субъекта // Клиническая информатика и телемедицина. - 2014. - Т. 10, № 11. - C. 119-122; Черняк Б.А., Трофименко И.Н. Влияние терапии тиотропием на бронхиальную гиперреактивность и клинико-функциональные показатели у больных хронической обструктивной болезнью легких // Пульмонология. - 2012. - № 2. - C. 46-51; Gosens R, Bos IS, Zaagsma J, Meurs H. (2005). Protective effects of tiotropium bromidein the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med, 171, 1096-1102.; Jones PW, Quirk FH, Baveystock SM. (1991). The St George’s Respiratory Questionnaire. Respir Med, 85 (Suppl B), 25-31.; Juniper EF, Svennson K. (2005). Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med, 99 (5), 533-538; Kang JY, Rhee CK, Kim JS. (2012). Effect of tiotropium bromide on airway remodeling in a chronic asthma model. Ann Allergy Asthma Immunol, 109, 29-35.; Kerstjens HAM, Disse B, Shroder-Babo W. (2011). Tiotropium improves lung function in patients with uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol, 128 (2), 308-314.; Kerstjens HAM, Engle M, Dahl R. (2012). Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med, 367, 1257-1259.; Miller MR, Crapo R, Hamkinson J, Brusasko V, Burgos F, Casaburi R, Coates A, Enright P. (2005). General consideration of lung function testing. Eur Resp Journal, 26 (1), 153-161.; Pera T, Ziudhof A, Valadas J, Smit M, Shoemaker RG, Gosens R, Maarsingh H, Zaagsma J, Meurs H. (2011). Tiotropium inhibits pulmonary inflammation and remodeling in a guinea pig model. Eur Respir J, 38 (4), 789-796.; Peters SP, Kunselman SJ, Icitovic N. (2010). Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med, 363 (18), 17151726.; Tashkin DP, Celli B, Senn S. (2008). A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 359 (15), 1543-1544.; Ullah MU, Khan MB, Liaqat J, Iftikhar R, Kamran SM, Khalil A. (2013). Role of tiotropium as step up therapy for asthma. Journal of Rawalpindi Medical College, 17 (2), 169-171.; Vogelmeier C, Hederer B, Glaab T. (2011). Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med, 364, 1093-1103.; https://www.actabiomedica.ru/jour/article/view/554

الاتاحة: https://www.actabiomedica.ru/jour/article/view/554
https://doi.org/10.29413/ABS.2018-3.2.4

المؤلفون: N. M. Nenasheva

المصدر: Медицинский совет, Vol 0, Iss 6, Pp 16-26 (2013)

مصطلحات موضوعية: тяжелая астма, фенотипы, эндотипы, омализумаб, тиотропия бромид, ингибиторы ть2-цитокинов, severe asthma, phenotypes endotypes, omalizumab, tiotropium bromide, th2 cytokine inhibitors, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/1199; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/d22d5d071ca1488b970e58a34615870e

المؤلفون: E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, Е. Г. Косолапов, Ф. С. Коченков, Н. Л. Погудина, Д. В. Блинов

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 10, No 2 (2017); 31-40 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 10, No 2 (2017); 31-40 ; 2070-4933 ; 2070-4909 ; 10.17749/2070-4909.2017.10.2

مصطلحات موضوعية: анализ влияния на бюджет, COPD, long-acting beta-agonists, LAAC, long-acting anticholinergics, vilantererol, umeclidinum bromide, tiotropium bromide, cost-effectiveness analysis, cost-utility analysis, budget impact analysis, ХОБЛ, длительно действующие бета-агонисты, ДДБА, длительно действующие антихолинергики, ДДАХ, вилантерол, умеклидиния бромид, тиотропия бромид, анализ «затраты-эффективность», анализ «затраты-полезность»

وصف الملف: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/197/190; Овчаренко С. И. Подходы к лечению хронической обструктивной болезни легких при стабильном течении. Лечебное Дело. 2004; 2: 24-30.; Gershon A. S. et al. Forecasting Health Services Use In Individuals With Chronic Obstructive Pulmonary Disease (COPD): A Time-Series Analysis //C96. Global Perspectives on COPD Burden and Care Delivery. American Thoracic Society. 2016; A6159-A6159.; Mannino D. M. et al. Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013. International Journal of COPD. 2014; 9: 597-611.; Crighton E. J. et al. A spatial analysis of COPD prevalence, incidence, mortality and health service use in Ontario. Health reports. 2015; 26 (3): 10.; Evans J. et al. Estimating the prevalence of COPD in Canada: Reported diagnosis versus measured airflow obstruction. Health reports. 2014; 25 (3): 3.; Гайгольник Т. В., Демко И. В., Бочанова Е. Н., Крапошина А. Ю., Гордеева Н. В., Соловьева И. А. Фармакоэкономический анализ затрат на обеспечение льготными лекарственными препаратами больных хронической обструктивной болезнью легких на территории Красноярского края. ФАРМАКОЭКОНОМИКА. Современная Фармакоэкономика и Фармакоэпидемиология. 2016; 2: 49-59. DOI:10.17749/2070-4909.2016.9.2.049-059.; Доклад ВОЗ. Хроническая обструктивная болезнь легких (ХОБЛ): Информационный бюллетень №315, 2015. URL: http://www.who.int/mediacentre/factsheets/fs315/ru/. Дата обращения: 28.12.2016.; Видякина Е. Э., Мальчикова С. В. Фармакоэкономический анализ терапии пациентов с хронической обструктивной болезнью легких в стационарных условиях. ФАРМАКОЭКОНОМИКА. Современная Фармакоэкономика и Фармакоэпидемиология. 2016; 2: 45-48. DOI:10.17749/2070-4909.2016.9.2.045-048.; Chuchalin A. G. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease. 2014; 9: 963-974.; Александрова Г. А., Поликарпов А. В., Голубев Н. А. с соавт. Заболеваемость всего населения России в 2015 году. Статистические материалы. Часть I. М. 2016; 139 с.; Александрова Г. А., Поликарпов А. В., Голубев Н. А. с соавт. Заболеваемость всего населения России в 2015 году. Статистические материалы. Часть II. М. 2016; 141 с.; Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. URL: http://goldcopd.org. Дата обращения: 17.03.2017.; Омельяновский В. В., Авксентьева М. В., Сура М. В., Герасимова К. В., Дзанаева А. В. Методические рекомендации по проведению сравнительной клинико-экономической оценки лекарственного препарата. М. 2016; 20 с.; Омельяновский В. В., Авксентьева М. В., Сура М. В., Хачатрян Г. Р., Федяева В. К. Методические рекомендации по оценке сравнительной клинической эффективности и безопасности лекарственного препарата. М. 2016; 58 с.; Омельяновский В. В., Авксентьева М. В., Сура М. В., Герасимова К. В., Дзанаева А. В. Методические рекомендации по оценке влияния на бюджет в рамках реализации программы государственных гарантий бесплатного оказания гражданам медицинской помощи. М. 2016; 28 с.; Starkie H. J., Briggs A. H., Chambers M. G., Jones P. Predicting EQ-5D values using the SGRQ. Value Health. 2011; 14 (2): 354-60.; Maleki-Yazdi M. R., Kaelin T., Richard N. et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014 Dec; 108 (12): 1752-60.; Аноро Эллипта. Инструкция по медицинскому применению. Государственный реестр Лекарственных Средств. URL: www.grls.rosminzdrav.ru. Дата обращения: 15.12.2016.; Спирива Респимат. Инструкция по медицинскому применению. Государственный реестр Лекарственных Средств. URL: www.grls.rosminzdrav.ru. Дата обращения: 15.12.2016.; Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2014 г.) / Пер. с англ. под ред. А. С. Белевского. М. 2014; 92 с.; Хроническая обструктивная болезнь легких. Клинические рекомендации. М. 2016; 69 с.; Макарова Е.В., Шумилова С.В., Вахламов В.А., Касатова Е.С., Меньков Н.В., Луковникова Н.Б., Варварина Г.Н., Тюрикова Л.В., Караулов А.В., Новиков В.В. Влияние неинвазивной вентиляции легких на функциональные и иммунные показатели у больных с тяжелым обострением хронической обструктивной болезни легких. Клиническая Медицина. 2017; 95 (4): 344-349.; Макарова Е.В., Варварина Г.Н., Меньков Н.В., Цапаева М.Ю., Лазарева Е.С., Казацкая Ж.А., Новиков В.В., Караулов А.В. Небулизированный будесонид в лечении обострений хронической обструктивной болезни легких: эффективность, безопасность и влияние на содержание растворимых дифференцировочных молекул в сыворотке крови. Терапевтический архив. 2016; 88 (3): 24-31.; https://www.pharmacoeconomics.ru/jour/article/view/197

الاتاحة: https://www.pharmacoeconomics.ru/jour/article/view/197
https://doi.org/10.17749/2070-4909.2017.10.2.031-040

المؤلفون: E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov, Е. Г. Косолапов, Ф. С. Коченков, Н. Л. Погудина, Д. В. Блинов, Н. Л. Бондаренко, А. В. Караулов

المصدر: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 10, No 2 (2017); 22-30 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 10, No 2 (2017); 22-30 ; 2070-4933 ; 2070-4909 ; 10.17749/2070-4909.2017.10.2

مصطلحات موضوعية: анализ влияния на бюджет, COPD, long-acting beta-agonists, LABA, long-acting anticholinergics, LAAC, vilantererol, umeclidinum bromide, olodaterol, tiotropium bromide, fixed combination, cost minimization analysis, cost-effectiveness analysis, budget impact analysis, ХОБЛ, длительно действующие бета-агонисты, ДДБА, длительно действующие антихолинергики, ДДАХ, вилантерол, умеклидиния бромид, олодатерол, тиотропия бромид, фиксированная комбинация, анализ минимизации затрат, анализ «затраты-эффективность»

وصف الملف: application/pdf

Relation: https://www.pharmacoeconomics.ru/jour/article/view/196/188; Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. М. 2014; 41 с.; Хроническая обструктивная болезнь легких. Клинические рекомендации. М. 2016; 69 с.; Лещенко И. В., Авдеев С. Н. Хроническая обструктивная болезнь легких: индикаторы качества, алгоритм диагностики и терапии. РМЖ. 2016; 16: 1039-1046.; Vogelmeier C. F., Criner G. J., Martinez F. J., Anzueto A., Barnes P. J., Bourbeau J. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017; 49 (3).; Sulaiman I., Cushen B., Greene G., Seheult J., Seow D., Rawat F. et al. Objective Assessment of Adherence to Inhalers by COPD Patients. Am J Respir Crit Care Med. 2016; doi:10.1164/rccm.201604-0733OC.; Laube B. L., Janssens H. M., de Jongh F. H. C., Devadason S. G., Dhand R., Diot P. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011; 37 (6): 1308-31.; Magnussen H., Disse B., Rodriguez-Roisin R., Kirsten A., Watz H., Tetzlaff K. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014; 371 (14): 1285-94.; Singh D., Maleki-Yazdi M. R., Tombs L., Iqbal A., Fahy W. A., Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016; 11: 1413-24.; Yang I. A., Clarke M. S., Sim E. H., Fong K. M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2012; (7): CD002991.; Crim C., Dransfield M. T., Bourbeau J., Jones P. W., Hanania N. A., Mahler D. A. et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015; 12 (1): 27-34.; Roversi S., Corbetta L. Clini E GOLD 2017 recommendations for COPD patients: toward a more personalized approach. COPD Research and Practice. 2017; 3 (5).; Barnes PJ. Gold 2017: a new report. Chest. 2017; 151 (2): 245-246.; Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. URL: http://goldcopd.org. Дата обращения: 17.03.2017.; Ninane V., Vandevoorde J., Cataldo D. et al. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences. Respir Med. 2015 Nov; 109 (11): 1430-8.; Аноро Эллипта. Инструкция по медицинскому применению. Государственный реестр Лекарственных Средств. URL: www.grls.rosminzdrav.ru. Дата обращения: 15.12.2016.; Спиолто Респимат. Инструкция по медицинскому применению. Государственный реестр Лекарственных Средств. URL: www.grls.rosminzdrav.ru. Дата обращения: 15.12.2016.; Bouyssou T., Casarosa P., Naline E., Pestel S., Konetzki I., Devillier P. et al. Pharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010; 334: 53-62.; Slack R. J., Barrett V. J., Morrison V. S. et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013; 344 (1): 218-30.; Schlueter M., Gonzalez-Rojas N., Baldwin M. et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016 Apr; 10 (2): 89-104.; Calzetta L., Rogliani P., Matera M. G., Cazzola M. A. Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016 May; 149 (5): 1181-96.; Horita N., Goto A., Shibata Y., Ota E., Nakashima K., Nagai K., Kaneko T. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews. 2017; 2. Art. No.: CD012066.; Calzetta L., Rogliani P., Ora J. et al. LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment. Eur Respir Rev. 2017; 26: 160043.; Price D., Østrem A., Thomas M., Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes – a review. Int J Chron Obstruct Pulmon Dis. 2016 Dec 30; 12: 141-168.; Donohue J. F., Betts K. A., Xiaoyan Du. E. et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017; 12: 367-381.; Feldman G., Maltais F., Khindri S. et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016 Apr 7; 11: 719-30.; Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014; 2 (6): 472-486.; https://www.pharmacoeconomics.ru/jour/article/view/196

الاتاحة: https://www.pharmacoeconomics.ru/jour/article/view/196
https://doi.org/10.17749/2070-4909.2017.10.2.022-030

المؤلفون: S. V. Fedosenko, N. A. Kirillova

المصدر: Бюллетень сибирской медицины, Vol 10, Iss 1, Pp 92-96 (2011)

مصطلحات موضوعية: тиотропия бромид, хобл, тревога, депрессия, Medicine

وصف الملف: electronic resource

Relation: https://bulletin.ssmu.ru/jour/article/view/1322; https://doaj.org/toc/1682-0363; https://doaj.org/toc/1819-3684

URL الوصول: https://doaj.org/article/362930a9805846bda0d67217cba8fa4c

المؤلفون: S. N. Avdeev, С. Н. Авдеев

المصدر: PULMONOLOGIYA; Том 26, № 2 (2016); 231-237 ; Пульмонология; Том 26, № 2 (2016); 231-237 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2016-26-2

مصطلحات موضوعية: олодатерол, long-acting bronchodilators, early diagnosis, early-stage therapy, tiotropium bromide, olodaterol, длительно действующие бронходилататоры, комбинированная терапия, ранняя диагностика, ранняя терапия, тиотропия бромид

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/706/617; Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. The 2016 report is available on www.goldcopd.com; Hogg J.C., McDonough J.E., Suzuki M. Small airway obstruction in COPD: new insights based on micro-CT imaging and MRI imaging. Chest. 2013; 143: 1436–1443.; Decramer M., Janssens W., Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012; 379: 1341–1351.; Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370: 741–750.; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD. 2014; 9: 963–974.; Hoyert D.L., Xu J. Deaths: preliminary data for 2011. Natl. Vital. Stat. Rep. 2012; 61: 1–51.; Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic obstructive pulmonary disease surveillance – United States, 1971 – 2000. MMWR Surveill. Summ. 2002; 51 (SS06): 1–16.; Kessler R., Partridge M.R., Miravitlles M. et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur. Respir. J. 2011; 37: 264–272.; Kim Y.J., Lee B.K., Jung C.Y. et al. Patient’s perception of symptoms related to morning activity in chronic obstructive pulmonary disease: the SYMBOL study. Korean J. Intern. Med. 2012; 27: 426–435.; Joshi M., Joshi A., Bartter T. Symptom burden in chronic obstructive pulmonary disease and cancer. Curr. Opin. Pulm. Med. 2012; 18: 97–103.; Bárbara C., Moita J., Cardoso J. et al. The importance of dyspnoea in the diagnosis of chronic obstructive pulmonary disease − a descriptive analysis of a stable cohort in Portugal (SAFE Trial). Rev. Port. Pneumol. 2011; 17: 131–138.; Miravitlles M., Worth H., Soler Cataluña J.J. et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir. Res. 2014; 15: 122.; Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363: 1128–1138.; Nishimura K., Izumi T., Tsukino M., Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002; 121: 1434–1340.; Steer J., Norman E.M., Afolabi O.A. et al. Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012; 67: 117–121.; Burgel P.R., Nesme-Meyer P., Chanez P. et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009; 135: 975–982.; Watz H., Waschki B., Meyer T., Magnussen H. Physical activity in patients with COPD. Eur. Respir. J. 2009; 33: 262–272.; Vaes A.W., Garcia-Aymerich J., Marott J.L. et al. Changes in physical activity and all-cause mortality in COPD. Eur. Respir. J. 2014; 44: 1199–1209.; Curtis J.R., Patrick D.L. The assessment of health status among patients with COPD. Eur. Respir. J. 2003; 21 (Suppl. 41): 36s–45s.; Reardon J.Z., Lareau S.C., ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. Am. J. Med. 2006; 119 (10A): S32–S37.; Beeh K.M., Beier J. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv. Ther. 2010; 7: 150–159.; Tashkin D.P. Is a long-acting inhaled bronchodilator the first agent to use in stable chronic obstructive pulmonary disease? Curr. Opin. Pulm. Med. 2005; 11: 121–128.; Tashkin D.P., Ferguson G.T.Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir. Res. 2013; 14: 49.; Sutherland E.R., Cherniack R.M. Management of chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2689–2697.; Авдеев С.Н. Выбор оптимальной терапии при ранних стадиях хронической обструктивной болезни легких. Справочник поликлинического врача. 2009; 11: 27–31.; Rennard S., Decramer M., Calverley P.M. et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur. Respir. J. 2002; 20: 799–805.; Green M. How big are the bronchioles? St. Thomas Hosp. Gaz. 1965; 63: 136–139.; Pinto-Plata V.M., Celli-Cruz R.A., Vassaux C. et al. Differences in cardiopulmonary exercise test results by American Thoracic Society / European Respiratory Society – Global initiative for chronic obstructive lung disease stage categories and gender. Chest. 2007; 132; 1204–1211.; Pitta F., Troosters T., Spruit M.A. et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 972–977.; Tantucci C., Modina D. Lung function decline in COPD. Int. J. COPD. 2012; 7: 95–99.; Авдеев С.Н., Трушенко Н.В. Двойная бронходилатация – новая парадигма длительно терапии хронической обструктивной болезни легких. Практическая пульмонология. 2015; 3: 24–32.; Muruganandan S., Jayaram L. Profile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD. Int. J. COPD. 2015; 10: 1179–1189.; Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45: 969–979.; Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109: 1312–1319.; Ferguson G.T., Flezar M., Korn S. et al. Efficacy of tiotropium/olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv. Ther. 2015; 32: 523–536.; Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo. Poster PA2958 presented at the European Respiratory Society International Congress, Amsterdam, the Netherlands, 26−30 September 2015.; https://journal.pulmonology.ru/pulm/article/view/706

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/706
https://doi.org/10.18093/0869-0189-2016-26-2-231-237

المؤلفون: N. A. Kuzubova, E. S. Lebedeva, O. N. Titova, Н. А. Кузубова, Е. С. Лебедева, О. Н. Титова

المصدر: PULMONOLOGIYA; Том 25, № 5 (2015); 613-621 ; Пульмонология; Том 25, № 5 (2015); 613-621 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2015-25-5

مصطلحات موضوعية: ремоделинг, tiotropium, muscarinic receptor, acetylcholine, vanilloid receptor, inflammation, remodeling, тиотропия бромид, мускариновый рецептор, ацетилхолин, ванилоидный рецептор, воспаление

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/629/569; Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Update 2014. www.goldcopd.com; Wessler I., Kirkpatrick C.J. Acetylcholine beyond neurons: the nonneuronal cholinergic system in humans. Br. J. Pharmacol. 2008; 154 (8): 1558–1571.; Gosens R., Zaagsma J., Meurs H., Halayko A. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Res. 2006; 7: 73.; Alagha K., Palot A., Sofalvi T. et al. Longacting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther. Adv. Chronic. Dis. 2014; 5 (2): 85–98.; Ikeda T., Anisuzzaman A.S.M., Yoshiki H. et al. Regional quantification of muscarinic acetylcholine receptors and badrenoceptors in human airways. Br. J. Pharmacol. 2012; 166: 1804–1814.; Bateman E.D., Rennard S., Barnes P.J. et al. Alternative mechanisms for tiotropium. Pulm. Pharmacol. Ther. 2009; 22 (6): 533–542.; Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003; 124 (5): 1743–1748.; O’Donnell D.E., Fluge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Resp. J. 2004; 23 (6): 832–840.; Buels K.S., Fryer A.D. Muscarinic receptor antagonists: effects on pulmonary function. Handb. Exp. Pharmacol. 2012; 208: 317–341.; Tashkin D.P., Celli B., Senn S. et al. A 4year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554.; Celli B., Decramer M., Leimer I. et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010; 137 (1): 20–30.; Авдеев С.Н. Вопросы сердечнососудистой безопасности длительной терапии тиотропием пациентов с ХОБЛ. Consilium Medicum. 2012; 14 (3): 34–39. / Avdeev S.N. Issued of cardiovascular safety of longterm therapy with tiotropium in COPD patients. Consilium Medicum. 2012; 14 (3): 34–39 (in Russian).; Barnes P.J. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin. Chest Med. 2014; 35 (1): 71–86.; Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–501.; Karakiulakis G., Roth M. Muscarinic receptors and their antagonists in COPD: antiinflammatory and antiremodeling effects. Mediators Inflamm. 2012; 2012: 409580.; Pieper M.P. The nonneuronal cholinergic system as novel drug target in the airways. Life Sci. 2012; 91 (21–22): 1113–1118.; Meurs H., Dekkers B.G., Maarsingh H. et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm. Pharmacol. Ther. 2013; 26 (1): 145–155.; Koarai A., Traves S.L., Fenwick P.S. et al. Expression of muscarinic receptors by human macrophages. Eur. Respir. J. 2012; 39 (3): 698–704.; Moffatt J.D., Cocks T.M., Page C.P. Role of the epithelium and acetylcholine in mediating the contraction to 5hydrox ytryptamine in the mouse isolated trachea. Br. J. Pharmacol. 2004; 141 (7): 1159–1166.; Kistemaker L.E., Oenema T.A., Meurs H., Gosens R. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci. 2012; 91 (21–22): 1126–1133.; Xu Z.P., Devillier P., Xu G.N. et al. TNFαinduced CXCL8 production by A549 cells: involvement of the nonneuronal cholinergic system. Pharmacol. Res. 2013; 68 (1): 16–23.; Profita M., Giorgi R.D., Sala A. et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy. 2005; 60: 1361–1369.; Елшин Н.Д., Чухловин А.Б., Кузубова Н.А., Титова О.Н. Определение экспрессии генов CHRM3 и ADRB2 в лейкоцитах крови в процессе комплексного лечения хронической обструктивной болезни легких. / Мультидисциплинарные аспекты молекулярной медицины. СПб: Издательство Санкт'Петербургского государственного экономического университета; 2015: 71–72. / Elshin N.D., Chukhlovin A.B., Kuzubova N.A., Titova O.N. CHRM3 and ADRB2 gene expression in blood leukocytes during treatment of chronic obstructive pulmonary disease. / Multidisciplinary aspects of molecular medicine. SaintPetersburg: Izdatel'stvo Sankt'Peterburgskogo gosudarstvennogo ekonomicheskogo universiteta; 2015: 71–72 (in Russian).; Zhang L., Cheng Z., Liu W., Wu K. Expression of interleukin (IL)10, IL17A and IL22 in serum and sputum of stable chronic obstructive pulmonary disease patients. COPD. 2013; 10 (4): 459–465.; Profita M., Albano G.D., Riccobono L. et al. Increased levels of Th17 cells are associated with nonneuronal acetyl choline in COPD patients. Immunobiology. 2014; 219 (5):392–401.; Xu Z.P., Song Y., Yang K. et al. M3 mAChRmediated IL8 expression through PKC/NFκB signaling pathways. Inflamm. Res. 2014; 63 (6): 463–473.; Kolahian S., Shahbazfar A.A., TayefiNasrabadi H. et al. Tiotropium effects on airway inflammatory events in the catas an animal model for acute cigarette smokeinduced lung inflammation. Exp. Lung Res. 2014; 40 (6): 272–287.; Bühling F., Lieder N., Kühlmann U.C. et al. Tiotropium suppresses acetylcholineinduced release of chemotactic mediators in vitro. Respir. Med. 2007; 101 (11): 2386–2394.; Vacca G., Randerath W.J., Gillissen A. Inhibition of granulocyte migration by tiotropium bromide. Respir. Res. 2011; 12 (1): 24–29.; Santus P., Buccellati C., Centanni S. et al. Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol. Res. 2012; 66 (4): 343–348.; Yamaya M., Nishimura H., Hatachi Y. et al. Inhibitory effects of tiotropium on rhinovirus infection in human air way epithelial cells. Eur. Respir. J. 2012; 40 (1): 122–132.; van Koppen C.J., Kaiser B. Regulation of muscarinic acetylcholine receptor signaling. Pharmacol. Ther. 2003; 98 (2): 197–220.; Oenema T.A., Kolahian S., Nanninga J.E. et al. Proinflammatory mechanisms of muscarinic receptor stimulation in airway smooth muscle. Respir. Res. 2010; 11: article 130.; Suzaki I., Asano K., Shikama Y. et al. Suppression of IL8 production from airway cells by tiotropium bromide in vitro. Int. J. Chron. Obstruct. Pulm. Dis. 2011; 6: 439–448.; Profita M., Bonanno A., Montalbano A.M. et al. Cigarette smoke extract activates human bronchial epithelial cells affecting nonneuronal cholinergic system signalling in vitro. Life Sci. 2011; 89 (1–2): 36–43.; Profita M., Albano G.D., Montalbano A.M. et al. Acetylcholine leads to signal transducer and activator of transcription 1 (STAT1) mediated oxidative / nitrosative stress in human bronchial epithelial cell line. Biochim. Biophys. Acta. 2013; 1832 (12): 1949–1958.; Holownia A., Mroz R.M., Wielgat P. et al. Altered histone deacetylase activity and iNOS expression in cells isolated from induced sputum of COPD patients treated with tiotropium. Adv. Exp. Med. Biol. 2013; 788: 1–6.; Holownia A., Mroz R.M., Skopinski T. et al. Tiotropium increases PPAR? and decreases CREB in cells isolated from induced sputum of COPD patients. Adv. Exp. Med. Biol. 2013; 756: 9–14.; Kistemarker L.E., Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends Pharmacol. Sci. 2015; 36 (3): 164–171.; Pera T., Zuidhof A., Valadas J. et al. Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pigmodel of COPD. Eur. Respir. J. 2011; 38 (4): 789–796.; Arai N., Kondo M., Izumo T. et al. Inhibition of neutrophil elastaseinduced goblet cell metaplasia by tiotropium in mice. Eur. Respir. J. 2010; 35 (5): 1164–1171.; Gosens R., Bos I.S., Zaagsma J., Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am. J. Respir. Crit. Care Med. 2005; 171 (10): 1096–1102.; Asano K., Shikama Y., Shoji N. et al. Tiotropium bromide inhibits TGFβinduced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro. Int. J. Chron. Obsrtruct. Pulm. Dis. 2010; 5: 277–286.; Кузубова Н.А., Федин А.Н., Лебедева Е.С., Платонова И.С. Влияние различных вариантов терапии на сокращение бронхов крыс с моделированной обструктивной болезнью легких. Российский физиологический журнал им. И.М.Сеченова. 2014; 100 (9): 1049–1058. / Kuzubova N.A., Fedin A.N., Lebedeva E.S., Platonova I.S. Effects of different treatments on bronchial constriction in rat models of obstructive lung disease. Rossiyskiy fiziologicheskiy zhurnal im. I.M.Sechenova. 2014; 100 (9): 1049– 1058 (in Russian).; Birrell M.A., Bonvini S.J., Dubuis E. et al. Tiotropium modulates transient receptor potential V1 (TRPV1) in air way sensory nerves: A beneficial offtarget effect? J. Allergy Clin. Immunol. 2014; 133 (3): 679–687.e9.; Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.; Malmberg L.P., Rytilä P., Happonen P., Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 257–262.; Архипов В.В., Абросимов А.Г., Архипова Д.Е. Спирива Респимат – новое направление в лечении ХОБЛ. Русский медицинский журнал. 2013; 7: 379–383. / Arkhipov V.V., Abrosimov A.G., Arkhipova D.E. Spiriva Respimat is a novel approach to therapy of COPD. Russkiy meditsinskiy zhurnal. 2013; 7: 379–383 (in Russian).; Barczok M., Perleberg C., Kardos P., Hodder R. Presented at VIII Deutsches Aerosol Therapie Seminar, Marburg, Germany, November 2003. http://experts.respimat.com/presentation_kit/patient_preference.html; van Noord J.A., Cornelissen P.J., Aumann J.L. et al. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Respir. Med. 2009; 103 (1): 22–29.; https://journal.pulmonology.ru/pulm/article/view/629

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/629
https://doi.org/10.18093/0869-0189-2015-25-5-613-621

المؤلفون: S. N. Avdeev, С. Н. Авдеев

المصدر: PULMONOLOGIYA; Том 25, № 4 (2015); 469-476 ; Пульмонология; Том 25, № 4 (2015); 469-476 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2015-25-4

مصطلحات موضوعية: тиотропия бромид, prognosis, oxygen therapy, non invasive ventilation, lung transplantation, long acting bronchodilators, tiotropium bromide, прогноз, длительная кислородотерапия, неинвазивная вентиляция легких, трансплантация легких, длительно действующие бронходилататоры

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/606/551; Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projection. Eur. Respir. J. 2006; 27: 397–412.; Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.; Buist A.S., McBurnie M.A., Vollmer W.M. et al. International variation in the prevalence of COPD (the BOLD Study): a population based prevalence study. Lancet. 2007; 370: 741–750.; Жестков А.В., Косарев В.В., Бабанов С.А., Глазитов А.В. Эпидемиология и факторы риска хронической обструктивной болезни легких в крупном промышленном центре Среднего Поволжья. Профилактика заболеваний и укрепление здоровья. 2009; 1: 42–44. / Zhestkov A.V., Kosarev V.V., Babanov S.A., Glazitov A.V. Epidemiology and risk factors of chronic obstructive pulmonary disease in a large industrial center of the Middle Volga region. Profilaktika zabolevaniy i ukreplenie zdorov'ya. 2009; 1: 42–44 (in Russian).; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Intern. J. COPD. 2014; 9: 963–974.; Global Initiative for Chronic Obstructive Lung Diseas (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. The 2015 report is available on www.goldcopd.com; Hoyert D.L., Xu J. Deaths: preliminary data for 2011. Natl. Vital. Stat. Rep. 2012; 61: 1–51.; Mannino D.M., Homa D.M., Akinbami L.J. et al. Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971–2000. MMWR Surveillance Summaries. 2002; 51 (SS06): 1–16.; Burney P.G.J., Patel J., Newson R. et al. Global and region al trends in COPD mortality, 1990–2010. Eur. Respir. J. 2015; 45: 1239–1247.; Garcia I.S., Clarа P.C. Causes of death and prediction of mortality in COPD. Arch. Bronconeumol. 2010; 46: 343–346.; Fuso L., Incalzi R.A., Pistelli R. et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am. J. Med. 1995; 98: 272–277.; Vestbo J., Prescott E., Lange P. et al. Vital prognosis after hospitalization for COPD: a study of a random population sample. Respir. Med. 1998; 92: 772–776.; Hansen E.F., Phanareth K., Laursen L.C. et al. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 1267–1271.; Martinez F.J., Foster G., Curtis J.L. et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am. J. Respir. Crit. Care Med. 2006; 173: 1326–1334.; Ries A.L., Kaplan R.M., Limberg T.M., Prewitt L.M. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann. Intern. Med. 1995; 122: 823–832.; Anthonisen N.R., Wright E.C., Hodgkin J.E. Prognosis in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis.1986; 133: 14–20.; Tantucci C., Donati P., Nicosia F. et al. Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease. Respir. Med. 2008; 102: 613–619.; Casanova C., Cote C., de Torres J.P. et al. Inspiratory to total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 171: 591–597.; Boushy S.F., Coates E.D., Prognostic valie of pulmonary function tests in emphysema: with special reference to arterial blood studies. Am. Rev. Respir. Dis. 1964; 90: 553–563.; Kanner R.E., Renzetti A.D., Stanish W.M. et al. Predictors of survival in subjects with chronic airflow limitation. Am. J. Med. 1983; 74: 249–255.; Nizet T.A.C., van den Elshout F.J.J., Heijdra Y.F. et al. Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest. 2005; 127: 1904–1910.; Cooper C.B., Waterhouse J., Howard P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. Thorax. 1987; 42: 105–110.; Ahmadi Z., Bornefalk Hermansson A., Franklin K.A. et al. Hypo and hypercapnia predict mortality in oxygen dependent chronic obstructive pulmonary disease: a population based prospective study. Respir. Res. 2014, 15: 30.; Burrows B., Kettel L.J., Niden A.H., Rabinowitz M., Diener C.F. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N. Engl. J. Med. 1972; 286: 912–918.; Weitzenblum E., Hirth C., Ducolone A. et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981; 36: 752–758.; Chaouat A., Bugnet A.S., Kadaoui N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 189–194.; Schols A.M., Slangen J., Volovics L.,Wouters E.F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1791–1797.; Landbo C., Prescott E., Lange P., Vestbo J., Almdal T.P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 1856–1861.; Oga T., Nishimura K., Tsukino M., Sato S., Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am. J. Respir. Crit. Care Med. 2003; 167: 544–549.; Soler Cataluna J.J., Martinez Garcia M.A., Roman S.P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60: 925–931.; Suissa S., Dell'aniello S., Ernst P. Long term natural history of chronic obstructive pulmonary disease: severe exacer bations and mortality. Thorax. 2012; 67: 957–963.; Divo M., Cote C., de Torres J.P. et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012; 186:155–161.; Engstrom G., Lind P., Hedblad B. et al. Lung function and cardiovascular risk: relationship with inflammation sensitive plasma proteins. Circulation. 2002; 106: 2555–2560.; Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? Circulation. 2003; 107: 1514–1519.; Rossi A., Aisanov Z., Avdeev S. et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir. Med. 2015; 109: 785–802.; Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.; Seneff M.G., Wagner D.P., Wagner R.P. et al. Hospital and 1 year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA. 1995; 274: 1852–1857.; Almagro P., Calbo E., Ochoa de Echaguen A. et al. Mortality after hospitalization for COPD. Chest. 2002; 121: 1441–1448.; Connors A.F., Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 1996; 154: 959–967.; Wouters E.F. The burden of COPD in The Netherlands: results from the confronting COPD survey. Respir. Med. 2003; 97 (Suppl. C): S51–59.; Gunen H., Hacievliyagil S.S., Kosar F. et al. Factors affecting survival of hospitalised patients with COPD. Eur. Respir. J. 2005; 26: 234–241.; Kong G.K., Belman M.J., Weingarten S. Reducing length of stay for patients hospitalized with exacerbation of COPD by using a practice guideline. Chest. 1997; 111: 89–94.; Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet. 1981; i: 681–686.; Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391–398.; McEvoy R.D., Pierce R.J., Hillman D. et al. Nocturnal non invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax. 2009; 64: 561–566.; Kóhnlein T., Windisch W., Kóhler D. et al. Non invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir. Med. 2014; 2: 698–705.; Lahzami S., Bridevaux P.O., Soccal P.M. et al. Survival impact of lung transplantation for COPD. Eur. Respir. J. 2010; 36: 74–80.; Short P.M., Williamson P.A., Elder D.H. et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long acting β agonist therapy in COPD. Chest. 2012; 141: 81–86.; Tashkin D.P., Celli B., Senn S. et al. A 4 year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.; Celli B., Decramer M., Leimer I. et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010; 137; 20–30.; Neff A.L., Petty T.A. Long term continuous oxygen therapy in chronic airway obstruction: mortality in relation to corpulmonale, hypoxia and hypercapnia. Ann. Intern. Med. 1970; 72: 621–626.; Elliot M.W. Non invasive ventilation in chronic obstructive pulmonary disease. In: Simonds A.K., ed. Non Invasive Respiratory Support, 3rd ed. London: Hodder Arnold; 2007.; Leger P., Bedicam J.M., Cornette A. et al. Nasal intermittent positive pressure ventilation. Long term follow up in patients with severe chronic respiratory insufficiency. Chest. 1994; 105: 100–105.; Strumpf D.A., Millman R.P., Carlisle C.C. et al. Nocturnal positive pressure ventilation via nasal mask in patients with severe chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1991; 144: 1234–1239.; Marin J.M., Soriano J.B., Carrizo S.J. et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am. J. Respir. Crit. Care Med. 2010; 182: 325–331.; Hogg J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004; 364: 709–721.; Pauwels R.A., Lofdahl C.G., Laitinen L.A. et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N. Engl. J. Med. 1999; 340: 1948–1953.; Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297–1303.; Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902–1909.; Lofdahl C.G., Postma D.S., Pride N.B. et al. Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD. Eur. Respir. J. 2007; 29: 1115–1119.; Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.; Yohannes A.M., Connolly M., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 117–125.; Gershon A.S., Wang L., To T. et al. Survival with tiotropium compared to long acting beta 2 agonists in chronic obstructive pulmonary disease. J. COPD. 2008; 5: 229–234.; Lipworth B.J., Short P.M. Explaining differential effects of tiotropium on mortality in COPD. Thorax. 2013; 68: 589–590.; Jenkins C.R., Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax. 2013; 68: 5–7.; Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat Inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369: 1491–1501.; https://journal.pulmonology.ru/pulm/article/view/606

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/606
https://doi.org/10.18093/0869-0189-2015-25-4-469-476

المؤلفون: A. I. Sinopal'nikov, А. И. Синопальников

المصدر: PULMONOLOGIYA; № 6 (2014); 73-82 ; Пульмонология; № 6 (2014); 73-82 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2017-0-3

مصطلحات موضوعية: тиотропия бромид, bronchodilators, anticholinergics, tiotropium bromide, бронхолитические препараты, антихолинергические препараты

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/496/480; Atsou K., Chouaid C., Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe; systematic review. BMC Med. 2011; 9: 7–16. http://www.biomedcentral.com/1741-7015/9/7; Buist A.S., Vollmer W.M., McBumie M.A. Worldwide burden of COPD in highand low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int. J. Tuberc. Lung Dis. 2008; 12: 703–708.; Menezes A.M., Perez-Padilla R., Hallal P.C. et al. Worldwide burden of COPD in highand low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int. J. Tuberc. Lung Dis. 2008; 12: 709–712.; http://www.internationalcod.org; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD. 2014; 12: 963–974.; Aisanov Z., Bai C., Bauerle O. et al. Primary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the world. Int. J. COPD. 2012; 7: 1–12.; O'Donnell D.E., Aaron S., Bourbeau J. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007. Can. Respir. J. 2007; 14 (Suppl. B): 5B–32B.; Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med. 2011; 155: 179–191.; Broncopneumopatia cronica ostruttiva. Linee guida nazionali di riferimento er la prevenzione e la terapia. http:// www.agenas.it/images/agenas/pnlg/BPCO.pdf; Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2014). http://www.goldcopd.com/uploads/users/ files/GOLD_Report_2014_Oct30.pdf; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014; 3: 15–54. / Chuchalin A.G., Avdeev S.N., Aysanov Z.R. et al. Federal guidelines on diagnosis and management of chronic obstructive pulmonary disease. Pul'monologiya. 2014; 3: 15–54 (in Russian).; Ohar J.A., Donohue J.F. Monoand combination theray of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin. Resir. Crit. Care Med. 2010; 31: 321–333.; Johnson M., Rennard S. Alternative mechanisms for longacting beta(2)-adrenergic agonists in COPD. Chest. 2001; 120: 258–270.; Hanania N.A., Moore R.H. Anti-inflammatory activities of beta2-agonists. Cur. Drug Targets Inflam. Allergy. 2004; 3: 271–277.; Bennett W.D., Almond M.A., Zeman K.L. et al. Effect of salmeterol on mucociliary and cough clearance in chronic bronchitis. Pulm. Pharmacol. Ther. 2006; 19: 96–100.; Profita M., Giorgi R.D., Sala A. et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy. 2005; 60: 1361–1369.; CG101 chronic obstructive pulmonary disease (update): full guideline. London: National Institute for Health and Clinical Excellence; 2010. http://guidance.nice.org.uk/ CG101/Guidance; Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093–1103.; Chong J., Karner C., Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 9: CD009157.; Kesten S., Jara M., Wentworth C., Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest. 2006; 130: 1695–1703.; Kesten S., Celli B., Decramer M. et al. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 397–409.; Toy E.L., Beaulieu N.U., McHale J.M. et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource, and cost. Respir. Med. 2011; 105: 435–441.; Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med. J. 1975; 51 (Suppl. 7): 13–20.; Jackson M. "Divine stramonium": the rise and fall of smoking for asthma. Med. Hist. 2010; 54: 171–194.; Cazzola M., Page C.P., Calzetta L., Matera M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev. 2012; 64: 450–504.; Simons F.E. Anticholinergic drugs and the airways: "time future contained in time past". J. Allergy Clin. Immunol. 1987; 80: 239–242.; Restrepo R.D. Use of inhaled anticholinergic agents in obstructive airway disease. Respir. Care. 2007; 52: 833–851.; Barnes P.J. The pharmacological properties of tiotropium. Chest. 2000; 117 (2, Suppl.): 63S–66S.; Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable chronic obstructive disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1136–1142.; Gross N.J., Co E., Skorodin M.S. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989; 96: 984–987.; Gross N.J., Skorodin M.S. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 1984; 311: 421–425.; Meurs H., Dekkers B.G., Maarsingh H. et al. Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target. Pulm. Pharmacol. Ther. 2013; 26: 145–155.; Cazzola M., Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2013; 23: 257–267.; Nardini S., Camiciottoli G., Locicero S. et al. COPD: maximization of bronchodilation. Multidiscip. Respir. Med. 2014; 9: 50–60.; Sykes D.A., Dowling M.R., Leighton-Devies J. et al. The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium. J. Pharmacol. Exp. Ther. 2012; 343: 520–528.; Disse B., Reichl R., Seck G. et al. Ba 679 BR, a novel longacting anticholinergic bronchodilator. Life Sci. 1993; 52: 537–544.; Casarosa P., Bouyssou T., Germeyer S. et al. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs. J. Harmacol. Exp. Ther. 2009; 330: 660–668.; Haddad E.B., Patel H., Keeling J.E. et al. Pharmacological characterization of the muscarinic recetor anagonists, glycopyrrolate, in human and guinea-pig airways. Br. J. Pharmacol. 1999; 127: 413–420.; Singh D., Leaker B., Tutuneu A. Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD (Abstract). Eur. Respir. J. 2011; 38: 147s.; Verkindre C., Fucuchi Y., Flemale A. et al. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir. Med. 2010; 104: 1482–1489.; Breekveldt-Postma N.S., Koerselman J., Erkens J.A. et al. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir. Med. 2007; 101: 1398–1405.; Cramer J.A., Bradley-Kennedy C., Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can. Respir. J. 2007; 14: 25–29.; Beeh K.M., Beier J. The short, the long, and the "ultralong": why duration of bronchodilator action matters in chronic obstructive pulmonary disease. Adv. Ther. 2010; 27: 150–159.; Taube C., Lehnigk B., Paasch K. et al. Factor analysis of changes in dyspnae and lung function parameters after bronchodilation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 216–220.; Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217–224.; O'Donnell D.E., Voduc N., Fitzpatrick M., Webb K.A. Effect of salmeterol on the ventilator response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 24: 86–94.; Anzueto A., Tashkin D., Menjoge S., Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Ther. 2005; 18: 75–81.; Vincken W., van Noord J.A., Greefhorst A.P. et al. Dutch / Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209–216.; Gauhar U., Dransfield M., Cooper J.A. Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 391–395.; Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143: 317–326.; Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 122: 47–55.; Brusasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003; 58: 399–404.; Briggs D.D. Jr, Covelli H., Lapidus R. et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm. Pharmacol. Ther. 2005; 18: 397–404.; Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of long-acting beta-agonists in stable COPD: a systematic review. Chest. 2008; 133: 1079–1087.; Tashkin D.P., Celli B., Senn S. et al. for UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543–1554.; Anzueto A., Miravitlles M. Efficacy of tiotropium in the prevention of exacerbations of COPD. Ther. Adv. Respir. Dis. 2009; 3: 103–111.; Celli B., Decramer M., Kesten S. et al. Mortality in the 4-year of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 15: 948–955.; Gershon A.S., Wang L., To T. et al. Survival with tiotropium compared to long-acting beta-2-agonists in chronic obstructive pulmonary disease. COPD. 2008; 4: 229–234.; Burgel P.-R., Paillasseur J.-L., Dusser D. et al. Tiotropium might improve survival in subjects with COPD at high risk of mortality. Respir. Res. 2014; 15 (64): 1–10.; Cazzola M., Molimard M. The scientific rationale for combining long-acting beta-2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23: 257–267.; COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. A 85-day multicenter trial. Chest. 1994; 105: 1411–1419.; van Nord J.A., de Munck D.R., Bantje T.A. et al. Longterm treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. J. 2000; 15: 878–885.; Cazzola M., Tashkin D.P. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD. 2009; 6: 404–415.; van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care Respir. J. 2012; 21: 101–108.; Mahler D.A., D'Urzo A., Bateman E.D. et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomized, double-blind comparison. Thorax. 2012; 67: 781–788.; Matera M.G., Rogliani P., Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Exp. Opin. Pharmacother. 2014; 15: 961–977.; Aalbers R., Maleki-Yazdi M.R., Hamilton A. et al. Dosefinding study for tiotropium and olodaterol when administration in combination via Resimat inhaler in patients with COPD [abstract]. Eur. Respir. J. 2012; 40: 525–526s.; Johnson M. Corticosteroids: potential beta2-agonist and anticholinergic interactions in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2: 320–325; discussion 340–341.; Singh D., Brooks J., Hagan G. et al. Superiority of "triple" therapy with salmeterol / fluticasone propionate and tiotropium bromide versus in individual components in moderate to severe COPD. Thorax. 2008; 63: 592–598.; Perng D.W., Wu C.C., Su K.C. et al. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology. 2006; 11: 598–602.; Aaron S.D., Vandemheen K.L., Fergusson D. et al. Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545–555.; Lee T.A., Wilke C., Joo M. et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch. Intern. Med. 2009; 169: 1403–1410.; Rodrigo G.J., Plaza V., Casto-Rodriguez J.A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Ulm. Pharmacol. Ther. 2012; 25: 40–47.; Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomized clinical trials. Lancet. 2009; 374: 695–703.; Sun S.X., Marynchenko M., Banerjee R. et al. Cost-effectiveness analysis of roflumilast / tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J. Med. Econ. 2011; 14: 805–815.; Michele T.M., Pinheiro S., Iyasu S. The safety of tiotropium – the FDA's conclusions. N. Engl. J. Med. 2010; 363: 1097–1099.; Singh S., Loke Y.K., Enright P.L. et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and metaanalysis of randomized controlled trials. Br. Med. J. 2011; 342: d3215.1–9.; Verhamme K., Afonso A., Romio S. et al. Use of tiotropium Respimat SMI versus tiotropium HandiHaler and mortality in patients with COPD. Eur. Respir. J. 2013; 42: 606–615.; Jenkins C.R., Beasley R. Tiotropium Respimat increases the risk of mortality. Thorax. 2013; 68: 5–7.; Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and risk of death in COPD. N. Engl. J. Med. 2013; 369: 1491–1501.; Barnes N.C., Jones P.W., Davis K.J. Safety of tiotropium through the Handihaler: why did meta-analyses and database studies appear to give a false alarm? Thorax. 2014; 69: 598–599.; Yohanes A.M., Connoly M., Hanania N.A. Ten years of tiotropium: clinical impact and patient perspectives. Intern. J. COPD. 2013; 8: 117–125.; Dusser D., Bravo M.L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2006; 27: 547–555.; Powrie D.J., Wilkinson T.M., Donaldson G.C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur. Resir. J. 2007; 30: 472–478.; Tonnel A.B., Perez T., Grosbois J.M. et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int. J. COPD. 2008; 3: 301–310.; Reid D.J., Carlson A.A. Clinical use of aclidinium in patients with COPD. Intern. J. COPD. 2014; 9: 369–379.; Donohue J.F., Niewoehner D., Brooks J. et al. Safety and tolerability of once-daily umeclidinium / vilanterol 125 / 25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir. Res. 2014; 15: 78–86.; Kerwin E.M., D'Urzo A.D., Gelb A.F. et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012; 9: 90–101.; Jones P.W., Singh D., Bateman E.D. et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40: 830–836.; D'Urzo A.D., Ferguson G.T., van Noord J.A. et al. Efficacy and safety of once-daily NVA237 in patients with moderateto-severe COPD: the GLOW1 trial. Respir. Res. 2011; 12: 156–163.; https://journal.pulmonology.ru/pulm/article/view/496

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/496
https://doi.org/10.18093/0869-0189-2014-0-6-73-82

المؤلفون: A. F. Ivanov, B. A. Chernjak, А. Ф. Иванов, Б. А. Черняк

المصدر: PULMONOLOGIYA; № 4 (2014); 112-117 ; Пульмонология; № 4 (2014); 112-117 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2014-0-4

مصطلحات موضوعية: Респимат, tiotropium bromide, Respimat, тиотропия бромид

وصف الملف: application/pdf

Relation: https://journal.pulmonology.ru/pulm/article/view/447/447; Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma. UPDATED 2012. www.ginaasthma.org; National Asthma Education and Prevention Program. Expert panel report III. Guidelines for the Diagnosis and Management of Asthma. www.nhlbi.nih.gov; Matsumura Y. Inflammation induces glucucurticoid resistance in patients with bronchial asthma. AntiInflammatory AntiAllergy Agents Med. Chem. 2009; 8 (4): 377–386.; Ahmad Z., Singh S.K. Relative and additional bronchodilator response of salbutamol and ipratropium in smoker and nonsmoker asthmatics. J. Asthma. 2010; 47 (3): 340–343.; Tashkin D.P., Celli B., Senn S. et al. A 4year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1544.; Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093–1103.; Bateman E.D., Rennard S., Barnes P.J. et al. Alternative mechanisms of tiotropium. Pulm. Pharmacol. Ther. 2009; 22 (6): 533–542.; Gosens R., Bos I.S., Zaagsma J. et al. Protective effects of tiotropium bromidein the progression of airway smooth muscle remodeling. Am. J. Respir. Crit. Care Med. 2005; 171: 1096–1102.; Kang J.Y., Rhee C.K., Kim J.S. et al. Effect of tiotropium bromide on airway remodeling in a chronic asthma model. Ann. Allergy Asthma Immunol. 2012; 109: 29–35.; Pera T., Ziudhof A., Valadas J. et al. Tiotropium inhibits pulmonary inflammation and remodeling in a guinea pigmodel. Eur. Respir. J. 2011; 38: 789–796.; Черняк Б.А., Трофименко И.Н. Влияние терапии тиотропием на бронхиальную гиперреактивность и клиникофункциональные показатели у больных хронической обструктивной болезнью легких. Пульмонология. 2012; 2: 46–51. / Chernyak B.A., Trofimenko I.N. Effects of tiotropium bromide on bronchial hyperreactivity and clinical and functional parameters of patients with chronic obstructive pulmonary disease. Pul'monologiya. 2012; 2: 46–51 (in Russian).; Fardon T., Haggart K., Lee D.K. et al. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe per sistent asthma. Respir. Med. 2007; 101 (6): 1218–1228.; Peters S.P., Kunselman S.J., Icitovic N. et al. Tiotropium bromide stepup therapy for adults with uncontrolled asthma. N. Engl. J.Med. 2010; 363 (18): 1715–1726.; Kerstjens H.A.M., Disse B., Shroder'Babo W. et al. Tiotropium improves lumg function in patients with uncontrolled asthma: a randomized controlled trial. J. Allergy Clin. Immunol. 2011; 128 (2): 308–314.; Kerstjens H.A.M., Engle M., Dahl R. Tiotropium in asthma poorly controlled with standard combination therapy. N. Engl. J. Med. 2012; 367: 1257–1259.; Kerstjens H.A.M., Dahl R., Paggiaro P.L. et al. Tiotropium provides sustained bronchodilation in asthmatics with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines. Eur. Respir. J. 2012; 40 (Suppl. 56): 313.; Kerstjens H.A.M., Dahl R., Beck E. et al. Tiotropium reduces exacerbation in asthmatic patient with persistent airflow obstruction uncontrolled despite treatment in accordance with guidelines. Eur. Respir. J. 2012; 40 (Suppl. 56): 313.; Kerstjens H.A.M., Engel M., Moroni'Zentgraf P. et al. Tiotropium added to inhaled corticosteriods and longact ing b2agonists reduces episodes of asthma worsening, irrespective of selected patient baseline characteristic. Allergy. 2013; 68 (Suppl. 97): 41–42.; Dahl R., Paggiaro P., Egel M. Oncedaily tiotropium improves lung function and reduces asthma exacerbation /worsening in patients with symptomatic asthma, regardless of allergic status. Allergy. 2013; 68 (Suppl. 97): 40–41.; Ullah M.U., Khan M.B., Liaqat J. et al. Role of tiotropium as step up therapy for asthma. J. Rawalpindi Med.l College. 2013; 17 (2): 169–171.; Wechsler M.E., Lehman E., Lazarus S.C. et al. National Heart, Lung and Blood Institute's Asthma Clinical Research Network. Betaadrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. 2006; 173 (5): 512–526.; Park H.W., Yang M.S., Park C.S. et al. Additive role of tiotropium in severe asthmatics and Arg16Glu in ADRB2 as a potential marker to predict response. Allergy. 2009; 64 (5): 778–783.; Bateman E.D., Kornmann O., Schmidt P. et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16 Arg/Arg patients with asthma. J. Allergy Clin. Immunol. 2011; 128 (2): 315–322.; Magnussen H., Bugnas B., van Noord J. et al. Improvements with tiotropium in COPD patients with contomitant asthma. Respir. Med. 2008; 102 (1): 50–56.; Рубаник Т.В., Привалова Е.В., Сергеева Г.Р. и др. Опыт применеия тиотропия в лечении больных бронхиальной астмой и ХОБЛ. Атмосфера. Пульмонология и аллергология. 2009; 1: 26–30. / Rubanik T.V., Privalova E.V., Sergeeva G.R. et al. An experience of treatment with tiotropium bromide of patients with bronchial asthma and COPD. Atmosfera. Pul'monologiya i allergologiya. 2009; 1: 26–30 (in Russian).; Fahy J.V. Eosinophilic and neutrofilic inflammation in asthma: insights from clinical studies. Proc. Am. Thorac. Soc. 2009; 6 (3): 256–259.; Iwamoto H., Yokoyama A., Shiota N. et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur. Respir. J. 2008; 31 (6): 1379–1380.; Beeh K.M., Ablinger O., Moroni'Zentgraf P. et al. Oncedaily addon tiotropium: a dosefinding trial in adult patients with moderate persistent asthma. Allergy. 2013; 68 (Suppl. 97): 376–377.; https://journal.pulmonology.ru/pulm/article/view/447

الاتاحة: https://journal.pulmonology.ru/pulm/article/view/447
https://doi.org/10.18093/0869-0189-2014-0-4-112-117